Gene · 1308
COL17A1: collagen type XVII alpha 1 chain
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. COL17A1: collagen type XVII alpha 1 chain. Genes, record 1308. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1308
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UMD9 | Collagen alpha-1(XVII) chain | 1,497 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents41
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026042028 A | 2026-03-10 | 21 | Q9UMD9 | Espacenet |
| EP 4703376 A1 | 2026-03-04 | 90 | Q9UMD9 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 25419 | Q9UMD9 | Espacenet |
| US 12428468 B2 | 2025-09-30 | 9 | Q9UMD9 | Espacenet |
| US 12428469 B2 | 2025-09-30 | 9 | Q9UMD9 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1078 | Q9UMD9 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1078 | Q9UMD9 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 25419 | Q9UMD9 | Espacenet |
| JP 2024167302 A | 2024-12-03 | 21 | Q9UMD9 | Espacenet |
| US 12128122 B2 | 2024-10-29 | 21 | Q9UMD9 | Espacenet |
1 to 10 of 41
See all 41 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants824
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | COL17A1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
| P30AR075043 | University of Michigan Skin Biology and Diseases Resource-based Center | 4 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 4 | 2025 |
| P30AR075047 | Skin Biology Resource-Based Center at UCI | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R01AR043799 | Mechanisms of Epidermal Homeostasis and Early Neoplasia | 3 | 2025 |
| R01AR063070 | Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa | 3 | 2025 |
| P30AR069589 | Penn Skin Biology and Diseases Resource-based Center | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 824Source NIH's project files
See all 824 nih grantsPapers3,031
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa. | Mol Ther Nucleic Acids | 2026 | 42824587 | PubTator, text mining | PubMed |
| Exacerbation of Bullous Pemphigoid following a Closed Bone Fracture in an Elderly Patient: A Case Report. | Case Rep Dermatol | 2026 | 42820212 | PubTator, text mining | PubMed |
| Six Cases of Pemphigoid Nodularis during Treatment with Dipeptidyl Peptidase-4 Inhibitors. | Case Rep Dermatol | 2026 | 42813148 | PubTator, text mining | PubMed |
| Clinical remission despite persistent anti-BP180 antibodies in neonatal pemphigoid. | J Eur Acad Dermatol Venereol | 2026 | 42808694 | PubTator, text mining | PubMed |
| Blistering rash in an elderly patient. | J Hosp Med | 2026 | 42803220 | PubTator, text mining | PubMed |
| Coexistence of Erythrodermic Psoriasis and Bullous Pemphigoid: A Case Report. | Clin Cosmet Investig Dermatol | 2026 | 42770037 | PubTator, text mining | PubMed |
| Immune-Checkpoint-Inhibitor-Related Bullous Pemphigoid During Avelumab Maintenance Therapy in a Patient With Metastatic Renal Pelvic Carcinoma: A Case Report. | IJU Case Rep | 2026 | 42688408 | PubTator, text mining | PubMed |
| Repositioning omalizumab in dermatology: emerging indications and mechanism-based therapeutic insights. | Expert Opin Biol Ther | 2026 | 42664019 | PubTator, text mining | PubMed |
| Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report. | Front Med (Lausanne) | 2026 | 42656375 | PubTator, text mining | PubMed |
| Transcriptomic Profiling Identifies a Subset of Renal Tumors with Overlapping Features of Clear Cell Papillary Renal Cell Tumor and Renal Cell Carcinoma with Fibromyomatous Stroma. | Cancers (Basel) | 2026 | 42650024 | PubTator, text mining | PubMed |
1 to 10 of 3,031
See all 3,031 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1308
GET https://conductscience.org/api/genes/v1/1308/patents?page=2